- Novel Coronavirus
-
Drug Discovery Services
- Antiviral Drug Discovery
- Complement Therapy
- SARS-CoV-2 Aptamers
- Antisense Oligonucleotides
- Protease Inhibitors
- Inhibitor of Host Cell Protease
- Abelson Kinase Inhibitors
- RNA Synthesis Inhibitors
- Nucleoside Analogue
- Neuraminidase Inhibitors
- Neutralizing Antibody
- Antiviral Peptide
- Broad-spectrum Antiviral Drug
- Anti-Inflammatory Drugs
- High-Throughput Screening
- Vaccine Discovery
- Evaluation Platforms for SARS-CoV-2 Drugs
- Antiviral Drug Discovery
- IVD Immunoassays
- Products
- Resources
- About Us
Ponatinib (CAT#: Vinh-008SX)
| CAT | Size | Price | Quantity | |
|---|---|---|---|---|
| Vinh-008SX |
|
For Research Use Only. We do not provide direct services or products for patients.
- Product Overview
- 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide; AP-24534, Bcr-Abl and Multikinase Inhibitor
- Target
- SARS-CoV-2
- Molecular Formula
- C29H27F3N6O
- Molecular Weight
- 532.6 g/mol
- Purity
- >98% by HPLC
- Storage
- Store at -20°C.
- Introduction
- Highly potent pan-Bcr-Abl and multikinase inhibitor, protects against influenza A virus-induced death by suppressing cytokine storm in mouse models.
Online Inquiry
For Research Use Only. We do not provide direct services or products for patients.
For Research Use Only. We do not provide direct services or products for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Inquiry Basket